ZYXI - Earnings announcements

ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, will hold a conference call on Tuesday, November 18, 2025 at 9:00 AM Eastern Time to discuss its financial results for the third quarter ended September 30, 2025. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call. Date: Tuesday, November 18, 2025Time: 9:00 AM Eastern Time (7:00 PM Moun

ENGLEWOOD, Colo., July 31, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2025. Management Commentary  "In the second quarter of 2025, we completed two transformational events. First, we appointed Steven Dyson as our new CEO. Steven brings over 25 years of experience in the medical technology sector, primarily thro

ENGLEWOOD, Colo., July 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 31, 2025 at 4:15 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2025.  Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Thursday

ENGLEWOOD, Colo., April 29, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2025. Management Commentary  "In the first quarter of 2025, we continued to see steady orders for our pain management and private-labeled rehabilitation products. Total orders decreased 3% year-over-year, but our sales force headcount was ap

ENGLEWOOD, Colo., April 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, April 29, 2025 at 4:15 PM Eastern Time to discuss its financial results for the first quarter ended March 31, 2025.  Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Tuesday

ENGLEWOOD, Colo., March 11, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024. Key Highlights and Business Update FY 2024 orders increased 16% year-over-yearFY 2024 net revenue increased 4% to $192.4 millionFY 2024 net income of $3.0 million; Diluted EPS $0.09FY 2024 cash flow from operations of

ENGLEWOOD, Colo., March 3, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, March 11, 2025 at 4:15 PM Eastern Time to discuss its financial results for the fourth quarter and year ended December 31, 2024. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Da

ENGLEWOOD, Colo., Oct. 24, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the third quarter ended September 30, 2024. Key Third Quarter Highlights and Business Update Q3 2024 orders increased 13% year-over-year.Q3 2024 net revenue of $50.0 million.Q3 2024 net income of $2.4 million; Diluted EPS $0.07.Q3 2024 cash flow from operations of $7.1 millio

ENGLEWOOD, Colo., Oct. 16, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, October 24, 2024 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended September 30, 2024.  Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: T

Q2 2024 Revenue Increased 11% to $49.9 Million ENGLEWOOD, Colo., July 25, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2024. Key Second Quarter Highlights and Business Update Q2 2024 orders increased 20% year-over-year, the highest number of orders in Company history for the ninth consecutive quarter.Q2 2024 reve

ENGLEWOOD, Colo., July 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 25, 2024 at 4:15 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2024.  Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Thursday

Q1 2024 Revenue Increased 10% to $46.5 Million ENGLEWOOD, Colo., April 30, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2024. Key First Quarter Highlights and Business Update Q1 2024 revenue increased 10% year-over-year to $46.5 million; Q1 2024 revenue underperformed guidance of $47.5 million due to payments fro

ENGLEWOOD, Colo., April 18, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, April 30, 2024 at 4:15 PM Eastern Time to discuss its financial results for the first quarter ended March 31, 2024.  Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Tuesday

FY 2023 Revenue Increased 17% to $184.3 Million Company Announces Additional $20 Million Stock Repurchase Plan ENGLEWOOD, Colo., Feb. 29, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2023 and its Board of Directors has approved an additional program to repurchase up to $20.0 million of the Company's common stock.

ENGLEWOOD, Colo., Feb. 22, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, February 29, 2024 at 4:15 PM Eastern Time to discuss its financial results for the fourth quarter and full year ended December 31, 2023. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer se

ENGLEWOOD, Colo., Oct. 12, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, October 26, 2023 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended September 30, 2023.  Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: T

Q2 2023 Revenue increased 22% to $45.0 Million; EPS $0.09 ENGLEWOOD, Colo., July 27, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has reported its financial and operational results for the second quarter ended June 30, 2023. Key Second Quarter and Subsequent 2023 Highlights and Business Update Q2 2023 revenue increased 22% year-over-year to $45.0 million.Net income of $3.4 million; Diluted EPS $0.09.Or

ENGLEWOOD, Colo., July 20, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 27, 2023 at 4:15 PM Eastern Time to discuss its financial results for the second quarter, 2023 ended June 30, 2023. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Thu

ENGLEWOOD, Colo., April 27, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights: Revenue increased 36% year-over-year to $42.2 millionNet income of $1.6 million; Diluted EPS $0.04Orders increased 61% year-over-year; highest number of orders in Company history for the 4th consecutive quarterFirst Quarter 2

ENGLEWOOD, Colo., April 19, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report first quarter 2023 financial results on Thursday, April 27, 2023. Zynex's management will host a conference call and webcast at 2:15 p.m. MT / 4:15 p.m. ET that day to discuss the financial results and provide a corporate update. Webcast Details: Thursday, April 27, 2023 at 2:15 p.m. MT

ENGLEWOOD, Colo., March 13, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the fourth quarter and full year ended December 31, 2022. -  2022 Fourth Quarter Highlights:  Orders increased 48%; highest number of orders in Company history for the 3rd consecutive quarterRevenue increased 21% year over year to $48.8 millionNet income of $7.5 million; Diluted EPS $0.20Adjuste

ENGLEWOOD, Colo., March 10, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report fourth quarter  and full-year 2022 financial results on Monday, March 13, 2023. Zynex's management will host a conference call and webcast at 6:30 a.m. MT / 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. Webcast Details: Monday, March 13, 2023 at 

ENGLEWOOD, Colo., March 6, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will postpone the release of its fourth quarter and full year financial results and conference call initially scheduled for Monday, March 6, 2023 at 4:15 p.m. ET. The company will announce its fourth quarter and full year 2022 financial results and conference call schedule in a future press release

ENGLEWOOD, Colo., Feb. 23, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report fourth quarter  and full-year 2022 financial results on Monday, March 6, 2023. Zynex's management will host a conference call and webcast at 2:15 p.m. MT / 4:15 p.m. ET that day to discuss the financial results and provide a corporate update. Webcast Details: Monday, March 6, 2023 at 2:1

ENGLEWOOD, Colo., Oct. 27, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Highlights: Increased revenue 19% year-over-year to $41.5 millionReported net income of $4.9 million; Diluted EPS of $0.13; Adjusted EBITDA of $8.1 millionRecorded cash from operations of $7.4 million for the third quarterCompleted th

ENGLEWOOD, Colo., Oct. 13, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report third quarter 2022 financial results on Thursday, October 27, 2022. Zynex's management will host a conference call and webcast at 4:15 p.m. ET that day to discuss the financial results and provide a corporate update. Webcast Details: Thursday, October 27, 2022, at 2:15 p.m. MT / 4:15 p.m

ENGLEWOOD, Colo., July 28, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Highlights: Revenue increased 18% year over year to $36.8 millionNet income increased 19% to $3.3 million; Diluted EPS of $0.08Adjusted EBITDA increased 16% to $5.5 millionCompleted initial $10 million share buyback and announced an addi

ENGLEWOOD, Colo. , July 20, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report second quarter 2022 financial results on Thursday, July 28, 2022. Zynex's management will host a conference call and webcast at 4:15 p.m. ET that day to discuss the financial results and provide a corporate update. Webcast Details: Thursday, July 28, 2022 at 2:15 p.m. MT / 4:15 p.m. ETT

ENGLEWOOD, Colo., April 28, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the first quarter ended March 31, 2022. Highlights: Revenue increased 29% year over year to $31.1 million Net income increased 296% to $1.4 million; Diluted EPS of $0.03 Adjusted EBITDA increased 897% to $3.1 million Announced Share Buyback Program up to $10M over next 12 months First Quarter F

ENGLEWOOD, Colo., April 18, 2022 /PRNewswire/ -- April 18, 2022 – Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report first quarter 2022 financial results on Thursday, April 28, 2022. Zynex's management will host a conference call and webcast at 4:15 p.m. ET that day to discuss the financial results and provide a corporate update. Webcast Details: Thursday, April 28, 2022 at 2:15 p.m.

ENGLEWOOD, Colo., Feb. 24, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the fourth quarter and full year ended December 31, 2021. 2021 Full Year Revenue increased 63% year over year to $130.3 million Orders increased 89% Net income increased 88% to $17.1 million; Diluted EPS of $0.44 Adjusted EBITDA increased 95% to $26.7 million 6th straight year of profitability $4

ENGLEWOOD, Colo., Feb. 18, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today responded to a short report related to United Health Care's prescription coverage of its products.    "We do not expect Zynex to experience any material changes in revenue throughout 2022 due to shifts in United Healthcare's reimbursement program," said Thomas Sandgaard, CEO. "In fact, most of Zynex's commercial business insu

ENGLEWOOD, Colo., Feb. 8, 2022 /PRNewswire/ -- Zynex, Inc. ((ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report fourth quarter and full-year 2021 financial results on Thursday, February 24, 2022. Zynex's management will host a conference call and webcast at 2:15 p.m. MT / 4:15 p.m. ET that day to discuss the financial results and provide a corporate update. Webcast Details: Thursday, February 24, 2022 a

ENGLEWOOD, Colo., Nov. 2, 2021 /PRNewswire/ -- 2021 Third Quarter Revenue increased 74% year over year to $34.8 million Orders increased 70% Record net income of $6.1 million; Diluted EPS $0.17 Adjusted EBITDA $9.3 millionZynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported financial results for its third quarter ended September 30, 2021. Third Quarter Financial Results Summary: For

ENGLEWOOD, Colo., July 29, 2021 /PRNewswire/ -- 2021 Second Quarter Revenue increased 61% year over year to $31.0 million Orders increased 247% Net income of $2.8 million; Diluted EPS $0.08 Adjusted EBITDA $4.8 millionZynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported financial results for its second quarter ended June 30, 2021. Second Quarter Financial Results Summary: For the seco